Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Jun-2026 14:16 ET (28-Jun-2026 18:16 GMT/UTC)
Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.
Mass General Brigham study of more than 6,000 patients highlights the need for long-term personalized surveillance strategies
First major U.S. rollout of HPV self-collection shows benefits for patients and providers, including fewer pelvic exams and better follow-up for HPV-positive results